LARS2 and colorectal carcinoma: Next, we took the 57 genes concordantly differentially expressed with CDC42 (Supplementary Table 4) in the 453 TCGA CRC patients with sufficient clinical data and analyzed their prognosis value alone or in combination with CDC42. From this analysis, we found that the expression of three genes, CACNA2D2, LARS2 and REG1CP render improved prognostic value when combined with CDC42 (Figures 2D–2F), where in the case of LARS2 and REG1CP there was only a modest improvement.